CANbridge-B (01228.HK): GORYNIN® (Velaglucerase Beta) Initiates Registration and Commercialization Preparations in North Africa, Advancing Global Gaucher Disease Market Strategy

NewTimeSpace · 2026/07/30 17:59 · By Xuran Lin

NewTimeSpace News: CANbridge Pharmaceuticals Inc. (01228.HK) announced on July 30 that GORYNIN®, a treatment for Gaucher disease, has commenced registration and commercialization preparations in the North African market. GORYNIN® is the Company's first self-developed enzyme replacement therapy, approved in China in May 2025. The Company stated it will pursue a global market strategy, though it has yet to generate any sales revenue from North Africa, where the registration process remains subject to regulatory approval.

NewTimeSpace News: On July 30, 2026, CANbridge Pharmaceuticals Inc. (01228.HK) issued a voluntary announcement disclosing that the Group has fully commenced the registration process and commercialization preparations for GORYNIN® (velaglucerase beta for injection) in key North African markets, with all launch preparatory work progressing in an orderly manner.

GORYNIN^® is a long-term enzyme replacement therapy for the treatment of Gaucher disease. It was approved for marketing by the NMPA on May 15, 2025, representing the Company's first self-developed enzyme replacement therapy, for which the Company holds global proprietary rights. The Company is conducting a registration clinical trial to extend the eligible patient population to children aged 2 years and under 12 years.

The Company noted that the overseas expansion of GORYNIN^® into the North African market represents a significant milestone in its global Gaucher disease market strategy, which is expected to enhance treatment accessibility for patients in North Africa and enrich the Company's revenue structure over the medium to long term. As of the announcement date, the Company has not yet recorded any formal sales revenue from the North African market, and the registration process must complete regulatory approval before commercialization can be finalized.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

CANBRIDGE-B 01228.HK Commercialization